Application 125526
- Type
- BLA
- Sponsor
- GLAXOSMITHKLINE LLC
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 125526 | Nucala | mepolizumab | 351(a) | Rx | 2026-10-01 |
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | NUCALA | MEPOLIZUMAB | INJECTABLE;SUBCUTANEOUS LYOPHILIZED POWER | 100MG | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
NDC listings for this application page 1 of 1 ยท 11 matching rows.
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0881 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |